Abstract
e12525 Background: There is no known effective treatment for recurrent high-grade glioma (HGG) after bevacizumab failure. Putative mechanisms of resistance include increased pericyte coverage, mediated partly by platelet-derived growth factor receptors (PDGFR), and an infiltrative tumor growth pattern potentially dependent on src signaling. We explored the efficacy of dasatinib, a PDGFR and src inhibitor, in patients with recurrent HGG after bevacizumab failure. Methods: Adult patients with histologically confirmed HGG who failed bevacizumab therapy were treated with dasatinib 70-100 mg twice daily, either alone (n = 3), in combination with bevacizumab (n = 15), or in combination with another agent (n = 2) until tumor progression or unacceptable toxicity. Results: Twenty patients were treated. Median age was 53 years (range 32-66) and median KPS was 75 (range 40-90). Sixteen patients (80%) had glioblastoma and the other 4 (20%) anaplastic glioma. The median number of prior regimens was 4. Of 19 evaluable ...
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
